Publication | Closed Access

The organometallic ferrocene exhibits amplified anti-tumor activity by targeted delivery via highly selective ligands to αvβ3, αvβ6, or α5β1 integrins

Drug TargetingOrganometallic Ferrocene ExhibitsTherapeutic NanomaterialsTargeted DeliveryMedicineSelective LigandsDrug Delivery SystemsTumor TargetingAnti-cancer AgentPharmacologyBiomolecular Engineering